Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Mili Arora

Hematology Oncology | Hematology | Oncology
UC Davis Health
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
Offers Telehealth
16 Years of Experience

Advanced in WT1-Related Wilms Tumor Syndromes
UC Davis Health
Regents Of The Univ Of Ca
3850 G St, 
Merced, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mili Arora is a Hematologist Oncology specialist and a Hematologist in Merced, California. Dr. Arora has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Inflammatory Breast Cancer, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2009
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

REGENTS OF THE UNIV OF CA
3850 G St, Merced, CA 95340
Call: 209-384-6528

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drugs: tucatinib, T-DM1
Study Phase: Phase 3
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Procedure, Drug
Study Drugs: carboplatin, paclitaxel, atezolizumab
Study Phase: Phase 2
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drugs: Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Enobosarm, Pembrolizumab
Study Phase: Phase 2
View 6 Less Clinical Trials

14 Total Publications

Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
Journal: BMC cancer
Published: March 26, 2025
View All 14 Publications
Similar Doctors
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohamed E. Eldaly
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Mohamed E. Eldaly
Hematology Oncology | Hematology | Oncology

First Choice Physician Partners

880 E Tuolumne Rd, Suite 103, 
Turlock, CA 
 (23.6 miles away)
209-250-5320
Languages Spoken:
English, Arabic, French, Spanish
See accepted insurances

Mohamed Eldaly is a Hematologist Oncology specialist and a Hematologist in Turlock, California. Dr. Eldaly is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Inflammatory Breast Cancer, Breast Cancer, and Angiosarcoma.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Dexter T. Estrada
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Dexter T. Estrada
Hematology Oncology | Hematology | Oncology

California Cancer Associates For Research And Excellence Inc

7130 N Millbrook Ave, 
Fresno, CA 
 (52.0 miles away)
559-326-1222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dexter Estrada is a Hematologist Oncology specialist and a Hematologist in Fresno, California. Dr. Estrada is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Iron Deficiency Anemia, Familial Colorectal Cancer, Colorectal Cancer, and Childhood Iron Deficiency Anemia.

Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ravi D. Rao
Hematology Oncology | Hematology | Oncology
Advanced in WT1-Related Wilms Tumor Syndromes
Dr. Ravi D. Rao
Hematology Oncology | Hematology | Oncology

California Cancer Associates For Research And Excellence Inc

7130 N Millbrook Ave, 
Fresno, CA 
 (52.0 miles away)
559-326-1222
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ravi Rao is a Hematologist Oncology specialist and a Hematologist in Fresno, California. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Colorectal Cancer, and Familial Colorectal Cancer.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Arora's expertise for a condition
ConditionClose
    • Distinguished
    • Angiosarcoma
      Dr. Arora is
      Distinguished
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Breast Cancer
      Dr. Arora is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Inflammatory Breast Cancer
      Dr. Arora is
      Distinguished
      . Learn about Inflammatory Breast Cancer.
      See more Inflammatory Breast Cancer experts
    • Paget Disease of the Breast
      Dr. Arora is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Adrenocortical Carcinoma
      Dr. Arora is
      Advanced
      . Learn about Adrenocortical Carcinoma.
      See more Adrenocortical Carcinoma experts
    • Adult Soft Tissue Sarcoma
      Dr. Arora is
      Advanced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Anaplastic Thyroid Cancer
      Dr. Arora is
      Advanced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Clear Cell Sarcoma
      Dr. Arora is
      Advanced
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Arora is
      Advanced
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    • Febrile Neutropenia
      Dr. Arora is
      Advanced
      . Learn about Febrile Neutropenia.
      See more Febrile Neutropenia experts
    View All 15 Advanced Conditions
    • Experienced
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Arora is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Arora is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Arora is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Arora is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adrenal Cancer
      Dr. Arora is
      Experienced
      . Learn about Adrenal Cancer.
      See more Adrenal Cancer experts
    • Agranulocytosis
      Dr. Arora is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    View All 92 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved